Ultimovacs ASA announced that the results from the UV1 Phase II clinical trial NIPU will be presented at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023. The presentation title is "First survival data from the NIPU trial; A randomized, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma". Principal Investigator Aslaug Helland, Professor at Oslo University Hospital, will give the presentation.

The NIPU study is an investigator-initiated Phase II clinical trial sponsored by Oslo University Hospital with support from Bristol-Myers Squibb and Ultimovacs. The study was designed to investigate if combining UV1 with the checkpoint inhibitors ipilimumab and nivolumab would provide a benefit compared to ipilimumab and nIVolumab alone, in patients with malignant pleural mesothelioma as a second-line treatment, after first-line treatment with platinum-based chemotherapy. The randomized, open-label, multi-center trial with 118 patients was conducted in Australia, Denmark, Norway, Spain and Sweden.